Navigation Links
Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1
Date:8/21/2007

Enterprise-Wide Solutions Designed to Increase Efficiency

MINNEAPOLIS, Aug. 21 /PRNewswire-FirstCall/ -- Vital Images, Inc. (Nasdaq: VTAL), a leading provider of enterprise-wide advanced visualization and analysis solutions, today announced it has released its next generation enterprise-wide advanced visualization and analysis product solutions with the release of Vitrea(R) 4.0 and ViTALConnect(R) 4.1. This comprehensive package offers powerful advanced visualization and analysis capabilities via workstation clients, remote clients and Web-based clients. These releases include significant enhancements to the company's powerful cardiovascular, neurovascular and gastrointestinal applications as well as improved Web-based cardiovascular analysis and distribution capabilities. In addition to the new version enhancements, the company also released ViTAL EP, a new electrophysiology (EP) planning application to augment its world class cardiovascular suite of products and Medicsight's ColonCAD(TM) for its InnerviewGI(TM) virtual colonoscopy application.

"Vital Images' Vitrea workstation-client set the productivity standard for advanced visualization and analysis clinical solutions," said Jay D. Miller, president and chief executive officer for Vital Images. "We've taken that same 'complexity made simple' approach to provide the most powerful tools via our Web-client, giving customers the ability to access these tools from anywhere at any time."

Enhancements to the company's Vitrea 4.0 workstation-client release include cardiovascular workflow enhancements such as automatic segmentation and probing of the coronary tree, easier vessel management and labeling, easy centerline editing and comprehensive reporting with automatic population of findings. Neurovascular improvements include motion correction and simultaneous multi-slice computation for true 4D perfusion for stroke patients. This release also includes improved colon enhancements such as fly-through capabilities, polyp probe and automatic registration of prone and supine, among other significant usability improvements including computer aided detection (CAD) designed to identify suspicious regions in the colon.

ViTAL's Web-client enhancements in the ViTALConnect 4.1 release include new cardiovascular tools, including automatic segmentation of the coronary tree, centerline editing and automatic stenosis calculation all designed to increase efficiency and productivity. Additional enhancements include improved 2D performance and integrated reporting features. The combined workstation and Web-client solution enables a streamlined workflow designed to improve efficiency.

"What I demonstrated live at the recent Stanford course -- loading and analyzing a 5,020 slice study over the Web-client -- I could have done from my house using my laptop," said Dr. Tony DeFrance, medical director of the CVCTA Education Center in San Francisco. "I routinely use the 'workstation-client' but it's nice to know that I can use the same powerful tools remotely using the Web-client."

The new EP planning application, ViTAL EP, contains a 3D advanced visualization and modeling tool for the electrophysiology (EP) lab. ViTAL EP automatically segments out the pulmonary veins and creates a three dimensional anatomic model of the heart for super-imposed EP mapping. In addition to its powerful clinical features, ViTAL EP automatically exports a 3D model for display on the on the St. Jude Medical EnSite(R) System, which is used to facilitate therapy for the treatment of arrhythmias.

Medicsight ColonCAD(TM), designed to automatically identify suspect regions in the colon, is available in Europe with Vitrea 4.0, and will be available in the US pending FDA clearance.

About ViTALConnect(R)

ViTALConnect(R) software is a Web-enabled medical tool that allows physicians to use PCs or notebook computers to access interactive 2D, 3D and 4D advanced visualization. Building on Vital Images' knowledge and understanding of advanced diagnostic workflow, ViTALConnect software offers users access that is critical in today's hospital environment. This solution enables users to review studies and perform advanced analysis -. from anywhere, at anytime. This communication tool includes collaboration capabilities that enable multiple physicians in different locations to confer while interacting with the same data in real-time.

About Vitrea(R)

Vitrea(R) software is Vital Images' advanced visualization solution that creates 2D, 3D and 4D images of human anatomy from CT (computed tomography) and MR (magnetic resonance) image data. With this productivity-enhancing tool, physicians can easily navigate within these images to better understand disease conditions. The Vitrea product addresses specialists' needs through various software options for cardiac, colon, vessel probe and other applications. In addition, Vitrea software utilizes an intuitive clinical workflow and automatic settings to improve speed and simplicity. Other capabilities and partnerships with PACS (picture archiving and communications systems) providers expand physicians' access to Vitrea software throughout an enterprise.

About Vital Images, Inc.

Vital Images, Inc., headquartered in Minneapolis, is a leading provider of enterprise-wide advanced visualization and analysis software solutions. The company's technology gives radiologists, cardiologists, oncologists and other medical specialists time-saving productivity and communications tools that can be accessed throughout the enterprise and via the Web for easy use in the day-to-day practice of medicine. Vital Images also has offices in Den Haag, Netherlands and Beijing, China. For more information, visit http://www.vitalimages.com.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties which could cause results to differ materially from those projected. Statements regarding past results are not predictions of future results, which could be affected by many factors, including but not limited to dependence on market growth, the timely availability and acceptance of new products, the impact of competitive products and pricing, dependence on major customers, third-party reimbursement, and other risks detailed from time to time in Vital Images' SEC reports, including its most recent Annual Report on Form 10-K for the year ended December 31, 2006.

Vitrea(R) and ViTALConnect(R) are registered trademarks of Vital Images. Vital Images disclaims any proprietary interest in the marks and names of others.


'/>"/>
SOURCE Vital Images, Inc.

Copyright©2007 PR Newswire.

Related biology technology :

1. Report Reveals Vitality of SE Wisconsin Technology Community
2. Counting Colonies or Plaques Directly from Images of Agar Plates
3. Madisons PunchStock acquired by Getty Images
4. TeraMEDICA offers seamless sharing of digital medical images
5. Images from new telescope to be released Thursday
6. Two Milwaukee finance IT firms agree to exchange check images
7. Merge eMed releases software upgrade
8. Sony releases tool for Blu-ray disc production
9. NameProtect releases annual list of top trademarkers
10. Small Tree releases fiber-optic gigabit Ethernet adapters for Mac OS X
11. Paragon releases MidMarkIT Suite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... services and solutions to the healthcare market. The company's primary focus is on ... sales and marketing strategies that are necessary to help companies efficiently bring their ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
Breaking Biology Technology:
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):